Avadel Pharmaceuticals plc: 2025 Annual Financial Report — Investor Highlights

Key Financial Results

• Return to Profitability: Avadel reported a net income of \$64.7 million for the year ended December 31, 2025, a significant turnaround from net losses of \$(48.8) million in 2024 and \$(160.3) million in 2023.
• Revenue Growth: Net product revenue surged to \$153.8 million in 2025 from \$27.1 million in 2024, reflecting robust commercial performance, primarily from LUMRYZ, the company’s only commercialized product.
• Operating Income: The company posted operating income of \$70.2 million in 2025, compared to operating losses of \$(42.4) million in 2024 and \$(137.8) million in 2023.
• EPS Recovery: Earnings per share (basic) was \$0.67 in 2025 versus \$(0.51) in 2024 and \$(2.00) in 2023. Diluted EPS was \$0.64 in 2025.
• Cash Position: Cash and cash equivalents increased markedly to \$165.4 million as of December 31, 2025, up from \$51.4 million at year-end 2024.
• Shareholders’ Equity: More than doubled to \$171.3 million at year-end 2025 from \$73.8 million in 2024.

Strategic and Operational Developments

• NASDAQ Direct Listing: Effective April 15, 2024, ordinary shares were directly listed on NASDAQ, following the termination of the American Depository Receipt (ADR) program. This transition may enhance liquidity and investor accessibility.
• Product Portfolio: LUMRYZ remains the sole commercialized product, but Avadel continues to evaluate portfolio expansion and has ongoing commercialization activities.
• Significant Capital Raises: In 2023 and 2024, Avadel executed public offerings and at-the-market issuances, raising substantial capital. For example, the April 2023 offering netted \$134 million, strengthening the balance sheet and supporting commercialization.
• Royalty Financing: The company entered a Royalty Purchase Agreement, reflected as a royalty financing obligation, measured using Level 3 inputs (unobservable), based on forecasted net product revenues.

Expense and Investment Breakdown

• Operating Expenses: Selling, general and administrative expenses were \$208.4 million in 2025, up from \$164.97 million in 2024 and \$137.85 million in 2023. R&D expenses also increased, reflecting ongoing development efforts.
• Share-Based Compensation: Total share-based compensation expense was \$19.8 million in 2025, with expectations for \$18.5 million in unrecognized expense related to granted but non-vested awards to be incurred over the next 1.9 years. All non-vested share-based compensation arrangements became fully vested, cancelled, or converted into cash rights upon the Alkermes transaction closing.
• Cash Flow: The company generated positive net cash from operating activities and benefited from investment and financing activities, including stock option exercises and public offerings.

Tax Matters and Regulatory Changes

• Tax Credits: Avadel benefits from R&D tax credits receivable from Irish authorities, totaling \$563,000 at year-end 2025.
• U.S. Tax Reform: The “One Big Beautiful Bill Act” (OBBBA), signed into law July 4, 2025, did not materially affect Avadel’s financials in 2025.
• Effective Tax Rate: Avadel recorded an income tax benefit of \$(1.89) million in 2025.

Legal and Contractual Commitments

• Legal Proceedings: The company faces two shareholder lawsuits (Levin v. Avadel Pharmaceuticals plc and Kent v. Avadel Pharmaceuticals plc) alleging proxy statement misrepresentations related to the Alkermes transaction. Avadel believes the claims are without merit and the transaction has closed, rendering injunction claims moot.
• Manufacturing Contract: Avadel has a three-year commitment with a CDMO for LUMRYZ manufacturing, valued between \$3.6 million and \$4.2 million annually.
• License Agreement: The company has entered into a License Agreement with contingent payment obligations related to its product portfolio.

Share Structure

• Ordinary Shares: As of December 31, 2025, Avadel had 98,092 ordinary shares issued and outstanding (nominal value \$0.01/share).
• Preferred Shares: No preferred shares outstanding at year-end.

Potential Price-Sensitive Issues for Shareholders

• Return to Profitability: The swing from losses to profit in 2025 is highly price-sensitive and may positively impact share value.
• Revenue Growth: The substantial increase in net product revenue indicates strong market adoption of LUMRYZ.
• Legal Risks: Ongoing litigation could affect investor sentiment, although Avadel believes the claims are without merit.
• Cash and Liquidity: Improved cash position provides stability and supports future growth initiatives.
• Direct NASDAQ Listing: Enhanced accessibility and liquidity for investors following ADR termination.
• Future Expense Recognition: All share-based compensation arrangements vested after the Alkermes transaction, which may affect future cash flows.

Conclusion

Avadel Pharmaceuticals plc’s 2025 financial results and strategic actions mark a crucial turnaround for the company, with strong revenue growth, a return to profitability, strengthened balance sheet, and liquidity. The direct NASDAQ listing, ongoing legal proceedings, significant capital raises, and manufacturing commitments represent key developments shareholders must monitor closely. The legal complaints, while believed to be without merit by the company, remain a potential risk factor.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information is based on Avadel Pharmaceuticals plc’s 2025 audited financial report and may be subject to change. Past performance is not indicative of future results.

View Alkermes plc. Historical chart here